NASDAQ:NEOG - Neogen Stock Price, News, & Analysis Sign in or create an account to add this stock to your watchlist. Get Started $62.23 -1.14 (-1.80 %) (As of 12/16/2018 10:33 AM ET)Previous Close$62.23Today's Range$61.83 - $63.325052-Week Range$54.09 - $97.38Volume126,108 shsAverage Volume210,575 shsMarket Capitalization$3.24 billionP/E Ratio51.43Dividend YieldN/ABeta1.38 ProfileDiscussionAnalyst RatingsChartEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email Neogen Corporation, together with its subsidiaries, develops, manufactures, and markets various products for food and animal safety worldwide. It operates through two segments, Food Safety and Animal Safety. The Food Safety segment primarily offers diagnostic test kits and complementary to detect dangerous and/or unintended substances in human food and animal feed, such as foodborne pathogens, spoilage organisms, natural toxins, food allergens, genetic modifications, ruminant by-products, meat speciation, drug residues, pesticide residues, and general sanitation concerns; and AccuPoint Advanced rapid sanitation test for adenosine triphosphate, a chemical found in living cells. This segment offers its products primarily to food and feed, and grain processors and processors; meat and poultry processors, seafood processors, fruit and vegetable producers, and dairies; laboratories; and producers of pharmaceuticals, cosmetics, veterinary vaccines, and nutraceutical products. The Animal Safety segment provides veterinary instruments, pharmaceuticals, vaccines, topical and diagnostic products, rodenticides, cleaners, disinfectants, insecticides, and genomics testing services for the animal safety market. This segment offers various products for researchers to detect biologically active substances. Its drug detection immunoassay test kits are used for the detection of abused and therapeutic drugs in farm and racing animals; detection of drug residues in meat and meat products; and human forensic toxicology drug screening applications. In addition, this segment's products are also used to maintain sanitary conditions and limit the potential hazards of bacteria, fungi, and viruses. The company sells its products directly, as well as through distributors and retail chains. Neogen Corporation was founded in 1981 and is headquartered in Lansing, Michigan. Receive NEOG News and Ratings via Email Sign-up to receive the latest news and ratings for NEOG and its competitors with MarketBeat's FREE daily newsletter. Industry, Sector and Symbol Stock Exchange NASDAQ Industry Diagnostic substances Sub-IndustryHealth Care Supplies SectorMedical Current SymbolNASDAQ:NEOG Previous Symbol CUSIP64049110 Webwww.neogen.com Phone517-372-9200 Debt Debt-to-Equity RatioN/A Current Ratio10.10 Quick Ratio8.09 Price-To-Earnings Trailing P/E Ratio51.43 Forward P/E Ratio50.19 P/E GrowthN/A Sales & Book Value Annual Sales$402.25 million Price / Sales8.04 Cash Flow$1.5546 per share Price / Cash Flow40.03 Book Value$10.86 per share Price / Book5.73 Profitability EPS (Most Recent Fiscal Year)$1.21 Net Income$63.14 million Net Margins16.35% Return on Equity12.06% Return on Assets10.92% Miscellaneous Employees1,546 Outstanding Shares51,990,000Market Cap$3.24 billion OptionableOptionable Neogen (NASDAQ:NEOG) Frequently Asked Questions What is Neogen's stock symbol? Neogen trades on the NASDAQ under the ticker symbol "NEOG." When did Neogen's stock split? How did Neogen's stock split work? Shares of Neogen split before market open on Tuesday, January 2nd 2018. The 4-3 split was announced on Friday, December 8th 2017. The newly created shares were distributed to shareholders after the closing bell on Friday, December 29th 2017. An investor that had 100 shares of Neogen stock prior to the split would have 133 shares after the split. How will Neogen's stock buyback program work? Neogen announced that its Board of Directors has authorized a share buyback plan on Wednesday, October 10th 2018, which authorizes the company to repurchase 3,000,000 outstanding shares, according to EventVestor. This repurchase authorization authorizes the company to reacquire shares of its stock through open market purchases. Shares repurchase plans are generally a sign that the company's board believes its stock is undervalued. How were Neogen's earnings last quarter? Neogen Co. (NASDAQ:NEOG) issued its quarterly earnings results on Tuesday, September, 25th. The company reported $0.29 earnings per share for the quarter, beating the Zacks' consensus estimate of $0.28 by $0.01. The business earned $99.60 million during the quarter, compared to the consensus estimate of $104.43 million. Neogen had a net margin of 16.35% and a return on equity of 12.06%. The company's quarterly revenue was up 5.7% compared to the same quarter last year. During the same period last year, the company earned $0.31 EPS. View Neogen's Earnings History. When is Neogen's next earnings date? Neogen is scheduled to release their next quarterly earnings announcement on Thursday, December 20th 2018. View Earnings Estimates for Neogen. How can I listen to Neogen's earnings call? Neogen will be holding an earnings conference call on Thursday, December 20th at 11:00 AM Eastern. Interested parties can register for or listen to the call using this link or dial in at 8004470521. What price target have analysts set for NEOG? 3 brokerages have issued 12-month target prices for Neogen's stock. Their predictions range from $62.00 to $70.00. On average, they anticipate Neogen's stock price to reach $65.6667 in the next twelve months. This suggests a possible upside of 5.5% from the stock's current price. View Analyst Price Targets for Neogen. What is the consensus analysts' recommendation for Neogen? 3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Neogen in the last year. There are currently 3 hold ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Neogen. Has Neogen been receiving favorable news coverage? News coverage about NEOG stock has been trending somewhat positive on Sunday, according to InfoTrie Sentiment. The research firm ranks the sentiment of media coverage by reviewing more than six thousand blog and news sources. The firm ranks coverage of companies on a scale of -5 to 5, with scores closest to five being the most favorable. Neogen earned a daily sentiment score of 1.0 on InfoTrie's scale. They also gave media coverage about the company a news buzz of 4.0 out of 10, meaning that recent media coverage is somewhat unlikely to have an impact on the stock's share price in the near term. Who are some of Neogen's key competitors? Some companies that are related to Neogen include IPSEN S A/S (IPSEY), Immunomedics (IMMU), Myriad Genetics (MYGN), Quidel (QDEL), Meridian Bioscience (VIVO), Intellia Therapeutics (NTLA), Lantheus (LNTH), Quotient (QTNT), Oxford Immunotec Global (OXFD), Nymox Pharmaceutical (NYMX), Trinity Biotech (TRIB), Celldex Therapeutics (CLDX), ImmuCell (ICCC), Vermillion (VRML) and Riot Blockchain (RIOT). Who are Neogen's key executives? Neogen's management team includes the folowing people: Mr. James L. Herbert, Exec. Chairman (Age 78)Mr. John Edward Adent, CEO & Pres (Age 50)Mr. Steven J. Quinlan, VP, CFO & Sec. (Age 56)Ms. Terri A. Morrical, VP of Animal Safety Operations (Age 53)Mr. Rod Poland, Director of Corp. Communications Who are Neogen's major shareholders? Neogen's stock is owned by a variety of of retail and institutional investors. Top institutional investors include BlackRock Inc. (14.32%), Vanguard Group Inc. (9.66%), Vanguard Group Inc (9.66%), Wasatch Advisors Inc. (3.56%), Conestoga Capital Advisors LLC (2.77%) and Riverbridge Partners LLC (1.82%). Company insiders that own Neogen stock include Edward Bradley, G Bruce Papesh, Jack C Parnell, James L Herbert, James P Tobin, John Edward Adent, Ronald D Green, Steven J Quinlan, Terri A Morrical, Thomas H Reed and William T Boehm. View Institutional Ownership Trends for Neogen. Which institutional investors are selling Neogen stock? NEOG stock was sold by a variety of institutional investors in the last quarter, including PNC Financial Services Group Inc., Loomis Sayles & Co. L P, Royce & Associates LP, WMS Partners LLC, Wasatch Advisors Inc., Janus Henderson Group PLC, Franklin Resources Inc. and King Luther Capital Management Corp. Company insiders that have sold Neogen company stock in the last year include Edward Bradley, G Bruce Papesh, Jack C Parnell, James L Herbert, Steven J Quinlan, Terri A Morrical, Thomas H Reed and William T Boehm. View Insider Buying and Selling for Neogen. Which institutional investors are buying Neogen stock? NEOG stock was bought by a variety of institutional investors in the last quarter, including BlackRock Inc., Conestoga Capital Advisors LLC, Vanguard Group Inc, Vanguard Group Inc., Carnegie Capital Asset Management LLC, Man Group plc, Morgan Stanley and Victory Capital Management Inc.. Company insiders that have bought Neogen stock in the last two years include James P Tobin and John Edward Adent. View Insider Buying and Selling for Neogen. How do I buy shares of Neogen? Shares of NEOG can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab. What is Neogen's stock price today? One share of NEOG stock can currently be purchased for approximately $62.23. How big of a company is Neogen? Neogen has a market capitalization of $3.24 billion and generates $402.25 million in revenue each year. The company earns $63.14 million in net income (profit) each year or $1.21 on an earnings per share basis. Neogen employs 1,546 workers across the globe. What is Neogen's official website? The official website for Neogen is http://www.neogen.com. How can I contact Neogen? Neogen's mailing address is 620 LESHER PLACE, LANSING MI, 48912. The company can be reached via phone at 517-372-9200 or via email at [email protected] MarketBeat Community Rating for Neogen (NASDAQ NEOG)Community Ranking: 2.2 out of 5 ( )Outperform Votes: 247 (Vote Outperform)Underperform Votes: 327 (Vote Underperform)Total Votes: 574MarketBeat's community ratings are surveys of what our community members think about Neogen and other stocks. Vote "Outperform" if you believe NEOG will outperform the S&P 500 over the long term. Vote "Underperform" if you believe NEOG will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 12/16/2018 by MarketBeat.com StaffFeatured Article: What do I need to know about analyst ratings?